[PDF][PDF] Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
…, SL Linderman, Z Moodie, J Czartoski, L Lai… - Cell Reports …, 2021 - cell.com
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …
[PDF][PDF] Rapid generation of neutralizing antibody responses in COVID-19 patients
…, RC Kauffman, G Mantus, SL Linderman… - Cell Reports …, 2020 - cell.com
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide
pandemic, and there is a pressing need to understand the development, specificity, and …
pandemic, and there is a pressing need to understand the development, specificity, and …
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season
SL Linderman, BS Chambers, SJ Zost… - Proceedings of the …, 2014 - National Acad Sciences
Influenza viruses typically cause the most severe disease in children and elderly individuals.
However, H1N1 viruses disproportionately affected middle-aged adults during the 2013–…
However, H1N1 viruses disproportionately affected middle-aged adults during the 2013–…
Cutting edge: IL-4, IL-21, and IFN-γ interact to govern T-bet and CD11c expression in TLR-activated B cells
…, RS Herati, B Bengsch, SL Linderman… - The Journal of …, 2016 - journals.aai.org
T-bet and CD11c expression in B cells is linked with IgG 2c isotype switching, virus-specific
immune responses, and humoral autoimmunity. However, the activation requisites and …
immune responses, and humoral autoimmunity. However, the activation requisites and …
Immune history shapes specificity of pandemic H1N1 influenza antibody responses
…, CB Sullivan, J Madara, SL Linderman… - Journal of Experimental …, 2013 - rupress.org
Human antibody responses against the 2009 pandemic H1N1 (pH1N1) virus are predominantly
directed against conserved epitopes in the stalk and receptor-binding domain of the …
directed against conserved epitopes in the stalk and receptor-binding domain of the …
Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination
…, MM McCausland, J Darce, C Chang, SL Linderman… - Science, 2020 - science.org
A universal vaccine against influenza would ideally generate protective immune responses
that are not only broadly reactive against multiple influenza strains but also long-lasting. …
that are not only broadly reactive against multiple influenza strains but also long-lasting. …
[HTML][HTML] Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma
…, JM Switchenko, A Chang, SL Linderman… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection
from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk …
from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk …
[HTML][HTML] Antibodies with 'original antigenic sin'properties are valuable components of secondary immune responses to influenza viruses
SL Linderman, SE Hensley - PLoS Pathogens, 2016 - journals.plos.org
Human antibodies (Abs) elicited by influenza viruses often bind with a high affinity to past
influenza virus strains, but paradoxically, do not bind to the viral strain actually eliciting the …
influenza virus strains, but paradoxically, do not bind to the viral strain actually eliciting the …
[HTML][HTML] Antibody response to COVID-19 mRNA vaccine in patients with lung cancer after primary immunization and booster: reactivity to the SARS-CoV-2 WT virus …
…, SL Linderman, A Akthar, RL Millett, L Lai… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE To examine COVID-19 mRNA vaccine–induced binding and neutralizing antibody
responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (…
responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (…
[HTML][HTML] Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic …
PURPOSE Patients with non-Hodgkin lymphoma including chronic lymphocytic leukemia (NHL/CLL)
are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine-…
are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine-…